Advertisement
UK markets closed

  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     

  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     

  • AIM

    790.50
    +6.80 (+0.87%)
     

  • GBP/EUR

    1.1627
    +0.0016 (+0.14%)
     

  • GBP/USD

    1.2526
    +0.0002 (+0.02%)
     

  • Bitcoin GBP

    48,689.18
    -901.04 (-1.82%)
     

  • CMC Crypto 200

    1,264.07
    -93.94 (-6.92%)
     

  • S&P 500

    5,216.71
    +2.63 (+0.05%)
     

  • DOW

    39,451.07
    +63.31 (+0.16%)
     

  • CRUDE OIL

    78.98
    -0.28 (-0.35%)
     

  • GOLD FUTURES

    2,371.70
    +31.40 (+1.34%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     

  • DAX

    18,772.85
    +86.25 (+0.46%)
     

  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     
MONEY:

Best savings accounts that offer above inflation rates

How to earn the most interest on your savings

Hikma first-half profit jumps on strong injectibles sales

Reuters - UK Focus

Aug 20 (Reuters) - Hikma Pharmaceuticals Plc (LSE: HIK.L - news) reported a 44 percent rise in first-half adjusted profit, helped by strong demand for its high-margin injectibles particularly in the United States.

Adjusted profit attributable to shareholders rose to $176 million in the six months ended June 30 from $122 million a year earlier.

Revenue at the Jordanian company, which makes and markets branded and non-branded generics and injectibles, rose 16 percent to $738 million.

Revenue rose 41 percent to $346 million at Hikma's injectibles business, accounting for 47 percent of total sales. (Reporting by Roshni Menon in Bangalore; Editing by Gopakumar Warrier)